Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001379513 | SCV001577325 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2020-08-09 | criteria provided, single submitter | clinical testing | Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PKHD1 are known to be pathogenic (PMID: 19940839). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with PKHD1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 58 of the PKHD1 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Fulgent Genetics, |
RCV002504635 | SCV002815386 | likely pathogenic | Polycystic kidney disease 4 | 2021-09-05 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV002504635 | SCV004202229 | pathogenic | Polycystic kidney disease 4 | 2023-10-20 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV001379513 | SCV002075534 | likely pathogenic | Autosomal recessive polycystic kidney disease | 2017-11-08 | no assertion criteria provided | clinical testing |